PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32170433-0 2020 CircAKT3 inhibits glycolysis balance in lung cancer cells by regulating miR-516b-5p/STAT3 to inhibit cisplatin sensitivity. Cisplatin 101-110 signal transducer and activator of transcription 3 Homo sapiens 84-89 33116826-1 2020 Objective: Constitutively activated signal transducer and activator of transcription 3 (STAT3) has been linked to cisplatin (DDP)-resistance in a wide range of cancers. Cisplatin 114-123 signal transducer and activator of transcription 3 Homo sapiens 36-86 33116826-1 2020 Objective: Constitutively activated signal transducer and activator of transcription 3 (STAT3) has been linked to cisplatin (DDP)-resistance in a wide range of cancers. Cisplatin 114-123 signal transducer and activator of transcription 3 Homo sapiens 88-93 33116826-1 2020 Objective: Constitutively activated signal transducer and activator of transcription 3 (STAT3) has been linked to cisplatin (DDP)-resistance in a wide range of cancers. Cisplatin 125-128 signal transducer and activator of transcription 3 Homo sapiens 36-86 33116826-1 2020 Objective: Constitutively activated signal transducer and activator of transcription 3 (STAT3) has been linked to cisplatin (DDP)-resistance in a wide range of cancers. Cisplatin 125-128 signal transducer and activator of transcription 3 Homo sapiens 88-93 33116826-11 2020 In agreement with previous studies that linked p-STAT3 levels to DDP-resistance, our in vitro and in vivo data indicate that tumors became more resistant to DDP-therapy with reduced ARHGAP6 levels and an associated increase in p-STAT3. Cisplatin 157-160 signal transducer and activator of transcription 3 Homo sapiens 49-54 33116826-11 2020 In agreement with previous studies that linked p-STAT3 levels to DDP-resistance, our in vitro and in vivo data indicate that tumors became more resistant to DDP-therapy with reduced ARHGAP6 levels and an associated increase in p-STAT3. Cisplatin 157-160 signal transducer and activator of transcription 3 Homo sapiens 229-234 32828740-6 2020 After treatment with cisplatin, we found that the expression of STAT3 and TGFB1 genes markedly increased in the neurosphere of the IMR-32 cell line, and TWIST1 was upregulated in the neurosphere of LN-18. Cisplatin 21-30 signal transducer and activator of transcription 3 Homo sapiens 64-69 32705214-0 2020 A small molecule STAT3 inhibitor, LLL12, enhances cisplatin- and paclitaxel-mediated inhibition of cell growth and migration in human ovarian cancer cells. Cisplatin 50-59 signal transducer and activator of transcription 3 Homo sapiens 17-22 32705214-3 2020 As previously reported, persistent STAT3 signaling is associated with resistance to cisplatin and paclitaxel. Cisplatin 84-93 signal transducer and activator of transcription 3 Homo sapiens 35-40 32705214-4 2020 To investigate whether the STAT3 small molecule inhibitor LLL12 can enhance the treatment effect of cisplatin and paclitaxel in ovarian cancer cells, A2780, SKOV3, CAOV-3 and OVCAR5 cells were treated with LLL12, cisplatin and paclitaxel, alone or combination, and cell viability, cell migration, cell growth and protein expression levels were then evaluated. Cisplatin 100-109 signal transducer and activator of transcription 3 Homo sapiens 27-32 32661236-12 2020 GAS5 was regulated by P-STAT3 and affected the sensitivity of CC to cisplatin-based chemotherapy through the miR-21/PDCD4 axis. Cisplatin 68-77 signal transducer and activator of transcription 3 Homo sapiens 24-29 33023532-13 2020 Treatment with cisplatin or paclitaxel significantly elevated the expression of TIMP-2 in Cont cells but not in T2-KD cells, consistent with significantly elevated expression of chemoresistance and CSC markers and activation of STAT3. Cisplatin 15-24 signal transducer and activator of transcription 3 Homo sapiens 228-233 32901049-0 2020 Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling. Cisplatin 29-38 signal transducer and activator of transcription 3 Homo sapiens 107-112 32901049-8 2020 Induction of epithelial-to-mesenchymal-transition (EMT) and activation of STAT3 signaling were determined to be the mechanisms underlying the CHRF-miR-10b axis-mediated cisplatin resistance. Cisplatin 169-178 signal transducer and activator of transcription 3 Homo sapiens 74-79 32252293-6 2020 Upon cisplatin treatment, CD44v6+ cells survive better and have lower apoptosis levels than CD44v6- cells, possibly due to concomitant activation of STAT3 and P38. Cisplatin 5-14 signal transducer and activator of transcription 3 Homo sapiens 149-154 32351887-0 2020 Combinatorial Low Dose Arsenic Trioxide and Cisplatin Exacerbates Autophagy via AMPK/STAT3 Signaling on Targeting Head and Neck Cancer Initiating Cells. Cisplatin 44-53 signal transducer and activator of transcription 3 Homo sapiens 85-90 32351887-12 2020 Together, low dose of combinatorial ATO/CDDP regimen induced cell death as well as exacerbated autophagy via AMPK-STAT3 mediated pathway in HN-CICs. Cisplatin 40-44 signal transducer and activator of transcription 3 Homo sapiens 114-119 32010312-0 2020 Interleukin-22 modulates cisplatin sensitivity of osteosarcoma cells by regulating the STAT3 signaling pathway. Cisplatin 25-34 signal transducer and activator of transcription 3 Homo sapiens 87-92 32080166-6 2020 We further identified that STAT3 functions to promote the transcription of the activating transcription factor 6 (ATF6), which induces endoplasmic reticulum stress to promote cellular autophagy, granting cancer cell resistance to both cisplatin and paclitaxel treatment. Cisplatin 235-244 signal transducer and activator of transcription 3 Homo sapiens 27-32 31974389-6 2020 Curcumin exerts permissive and chemosensitive properties by targeting the cisplatin chemoresistant factors Nrf-2, NF-kappaB and STAT-3 phosphorylation. Cisplatin 74-83 signal transducer and activator of transcription 3 Homo sapiens 128-134 31790894-16 2020 The combination of CDDP/PXD and TK or CuD inhibited p-AKT, p-Erk, and p-JNK signaling and suppressed Stat3 and NF-kappaB transcriptional activity in H1299 cells. Cisplatin 19-23 signal transducer and activator of transcription 3 Homo sapiens 101-106 31936675-5 2020 The cotreatment of PTC cell lines with curcumin and cisplatin synergistically potentiated cytotoxic effects via the suppression of JAK/STAT3 activity along with the inhibition of antiapoptotic genes and the induction of proapoptotic genes, and it also suppressed the migration of PTC cells by downregulating matrix metalloproteinases and the inhibition of colony formation. Cisplatin 52-61 signal transducer and activator of transcription 3 Homo sapiens 135-140 31936675-6 2020 Finally, thyrospheres treated with curcumin and cisplatin showed suppressed STAT3 phosphorylation, a reduced formation of thyrospheres, and the downregulated expression of stemness markers, in addition to apoptosis. Cisplatin 48-57 signal transducer and activator of transcription 3 Homo sapiens 76-81 31936675-7 2020 The current study"s findings suggest that curcumin synergistically enhances the anticancer activity of cisplatin in PTC cells as well as in cancer stem-like cells by targeting STAT3, which suggests that curcumin combined with chemotherapeutic agents may provide better therapeutic outcomes. Cisplatin 103-112 signal transducer and activator of transcription 3 Homo sapiens 176-181 32767949-0 2020 A Ferrocene Derivative Reduces Cisplatin Resistance in Breast Cancer Cells Through Suppression of MDR-1 Expression and Modulation of JAK2/STAT3 Signaling Pathway. Cisplatin 31-40 signal transducer and activator of transcription 3 Homo sapiens 138-143 32767949-7 2020 RESULTS: Overexpression of MDR1 as well as a markedly increase in the level of phosphorylated STAT3 was observed in cisplatin-resistant MCF-7 (MCF-7R) cells. Cisplatin 116-125 signal transducer and activator of transcription 3 Homo sapiens 94-99 32767949-8 2020 FMSP successfully reduced the MCF-7R cell viability and reversed both MDR1 expression and STAT3 phosphorylation status through which sensitivity of MCF-7R cells to cisplatin treatment was regained. Cisplatin 164-173 signal transducer and activator of transcription 3 Homo sapiens 90-95 32757663-0 2020 HOTAIR Promotes Cisplatin Resistance of Osteosarcoma Cells by Regulating Cell Proliferation, Invasion, and Apoptosis via miR-106a-5p/STAT3 Axis. Cisplatin 16-25 signal transducer and activator of transcription 3 Homo sapiens 133-138 31597912-0 2019 The crosstalk between STAT3 and p53/RAS signaling controls cancer cell metastasis and cisplatin resistance via the Slug/MAPK/PI3K/AKT-mediated regulation of EMT and autophagy. Cisplatin 86-95 signal transducer and activator of transcription 3 Homo sapiens 22-27 31037726-5 2019 c-Myb overexpression activated NF-kappaB and STAT3 signaling leading to enhanced proliferation, invasion, and cisplatin resistance. Cisplatin 110-119 signal transducer and activator of transcription 3 Homo sapiens 45-50 31878245-11 2019 In vivo, treatment with OV alone or in combination with CDDP significantly reduced the tumor sphere-forming ability and decreased EV cargos containing mTOR, PI3K, STAT3, beta-catenin, and miR-21-5p. Cisplatin 56-60 signal transducer and activator of transcription 3 Homo sapiens 163-168 31647948-0 2019 Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p. Cisplatin 23-32 signal transducer and activator of transcription 3 Homo sapiens 100-105 30811078-0 2019 The induction of ferroptosis by impairing STAT3/Nrf2/GPx4 signaling enhances the sensitivity of osteosarcoma cells to cisplatin. Cisplatin 118-127 signal transducer and activator of transcription 3 Homo sapiens 42-47 30811078-7 2019 Western blotting analysis indicated that protein levels of p-STAT3 (Ser727), nuclear factor erythroid 2-related factor 2 (Nrf2), and glutathione peroxidase 4 (GPx4) in drug-resistant strains increased significantly in response to cisplatin. Cisplatin 230-239 signal transducer and activator of transcription 3 Homo sapiens 61-66 30811078-10 2019 The reduction of protein levels of p-STAT3 (Ser727), Nrf2, and GPx4 in MG63/DDP and Saos-2/DDP cells resulted in increased ferroptosis and sensitivity to cisplatin. Cisplatin 154-163 signal transducer and activator of transcription 3 Homo sapiens 37-42 30811078-12 2019 However, ferroptosis agonists and STAT3 inhibitor reactivated ferroptosis in the cells and consequently increased sensitivity to cisplatin. Cisplatin 129-138 signal transducer and activator of transcription 3 Homo sapiens 34-39 31597912-4 2019 The phosphorylation of STAT3 at Y705 also activated the MAPK and PI3K/AKT signaling to inhibit the ERS-mediated autophagy through down-regulation of pPERK, pelf2alpha, ATF6alpha, and IRE1alpha, which led to increased cisplatin resistance. Cisplatin 217-226 signal transducer and activator of transcription 3 Homo sapiens 23-28 31597912-7 2019 Thus, our data provide strong evidence that the crosstalk between STAT3 and p53/RAS signaling controls ovarian cancer cell metastasis and cisplatin resistance via the Slug/MAPK/PI3K/AKT-mediated regulation of EMT and autophagy. Cisplatin 138-147 signal transducer and activator of transcription 3 Homo sapiens 66-71 31534119-0 2019 Dynasore suppresses cell proliferation, migration, and invasion and enhances the antitumor capacity of cisplatin via STAT3 pathway in osteosarcoma. Cisplatin 103-112 signal transducer and activator of transcription 3 Homo sapiens 117-122 31226634-0 2019 Targeting STAT3 inhibition to reverse cisplatin resistance. Cisplatin 38-47 signal transducer and activator of transcription 3 Homo sapiens 10-15 31226634-5 2019 In addition, STAT3 inhibitors have shown the ability to enhance the anti-tumor efficacy of cisplatin. Cisplatin 91-100 signal transducer and activator of transcription 3 Homo sapiens 13-18 31226634-6 2019 In this review, we summarized the current knowledge of the STAT3 pathway in cancer treatment and its contribution to cisplatin resistance. Cisplatin 117-126 signal transducer and activator of transcription 3 Homo sapiens 59-64 31226634-7 2019 Moreover, this review focuses on targeting STAT3 inhibition to overcome cisplatin resistance. Cisplatin 72-81 signal transducer and activator of transcription 3 Homo sapiens 43-48 31298375-0 2019 MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3. Cisplatin 56-65 signal transducer and activator of transcription 3 Homo sapiens 84-89 31182137-14 2019 Transcriptome analyses revealed that STAT1 and STAT3 activation enable AKR1C1-induced cisplatin-resistance and can be overcome by ruxolitinib treatment. Cisplatin 86-95 signal transducer and activator of transcription 3 Homo sapiens 47-52 31298375-14 2019 Moreover, it inhibits the invasion and metastasis capacities through targeting STAT3, which can serve as a therapeutic target for cisplatin-based chemotherapy resistance of NSCLC. Cisplatin 130-139 signal transducer and activator of transcription 3 Homo sapiens 79-84 30352127-0 2019 Growth arrest-specific 5 attenuates cisplatin-induced apoptosis in cervical cancer by regulating STAT3 signaling via miR-21. Cisplatin 36-45 signal transducer and activator of transcription 3 Homo sapiens 97-102 30808674-6 2019 RORC prevented the nuclear translocation of STAT3 via suppression of the PD-L1/ITGB6 signaling pathway, which further inhibited bladder cell proliferation and glucose metabolism and increased cisplatin-induced apoptosis. Cisplatin 192-201 signal transducer and activator of transcription 3 Homo sapiens 44-49 30777616-8 2019 Forced overexpression of STAT3 weakened the chemosensitivity of ANRIL-silenced cells to cisplatin. Cisplatin 88-97 signal transducer and activator of transcription 3 Homo sapiens 25-30 30483799-11 2019 These observations indicated that Epo was able to hinder the cytotoxic effect of cisplatin in cervical cancer cells by activating anti-apoptotic responses regulated by STAT3. Cisplatin 81-90 signal transducer and activator of transcription 3 Homo sapiens 168-173 30961670-0 2019 Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway. Cisplatin 69-78 signal transducer and activator of transcription 3 Homo sapiens 119-124 30961670-12 2019 Expressions of JAK1,2, STAT3 PD-L1 and ATM were increased in A549CisR and H157CisR cells and could by induced by cisplatin in parental lung cancer cells. Cisplatin 115-124 signal transducer and activator of transcription 3 Homo sapiens 24-29 30961670-17 2019 CONCLUSIONS: Our results show that ATM regulates PD-L1 expression through activation of JAK/STAT3 signaling in cisplatin-resistant cells. Cisplatin 111-120 signal transducer and activator of transcription 3 Homo sapiens 92-97 30747218-0 2019 Gallic acid has anticancer activity and enhances the anticancer effects of cisplatin in non-small cell lung cancer A549 cells via the JAK/STAT3 signaling pathway. Cisplatin 75-84 signal transducer and activator of transcription 3 Homo sapiens 138-143 30747218-6 2019 Furthermore, the results of the present study also demonstrated that GA exerted independent anticancer effects on NSCLC A549 cells, and facilitated the anticancer effects of cisplatin by modulating the JAK/STAT3 signaling pathway and downstream apoptotic molecules. Cisplatin 174-183 signal transducer and activator of transcription 3 Homo sapiens 206-211 31105696-11 2019 Cell functional assays showed that Atezolizumab in combination with Bevacizumab inhibited the proliferation, migration, and invasion of cisplatin resistant ovarian cancer cell line A2780cis in vitro synergistically, which maybe associate with Bevacizumab suppressing the epithelial-mesenchymal transition (EMT) and PD-L1 expression by targeting STAT3. Cisplatin 136-145 signal transducer and activator of transcription 3 Homo sapiens 345-350 30332965-9 2019 The results show that dasatinib exerts synergistic effects with cisplatin in human medulloblastoma cells through the inhibition of STAT3 and Src. Cisplatin 64-73 signal transducer and activator of transcription 3 Homo sapiens 131-136 29767234-0 2018 MicroRNA-125a-5p enhances the sensitivity of esophageal squamous cell carcinoma cells to cisplatin by suppressing the activation of the STAT3 signaling pathway. Cisplatin 89-98 signal transducer and activator of transcription 3 Homo sapiens 136-141 30347860-9 2018 The results indicated the potential benefit of combination therapy with HIF-1 and STAT3 inhibitors in overcoming HICR to free or micellar cisplatin. Cisplatin 138-147 signal transducer and activator of transcription 3 Homo sapiens 82-87 30099826-0 2018 LncRNA HOXA11-AS drives cisplatin resistance of human LUAD cells via modulating miR-454-3p/Stat3. Cisplatin 24-33 signal transducer and activator of transcription 3 Homo sapiens 91-96 30099826-10 2018 Next, the HOXA11-AS/miR-454-3p/Stat3 (signal transducer and activator of transcription 3) pathway was found to influence the cisplatin resistance of LUAD cells. Cisplatin 125-134 signal transducer and activator of transcription 3 Homo sapiens 31-36 30099826-10 2018 Next, the HOXA11-AS/miR-454-3p/Stat3 (signal transducer and activator of transcription 3) pathway was found to influence the cisplatin resistance of LUAD cells. Cisplatin 125-134 signal transducer and activator of transcription 3 Homo sapiens 38-88 30099826-14 2018 In conclusion, lncRNA HOXA11-AS acted as a ceRNA to promote cisplatin resistance of human LUAD cells via the miR-454-3p/Stat3 axis. Cisplatin 60-69 signal transducer and activator of transcription 3 Homo sapiens 120-125 30061175-0 2018 STAT3 regulated miR-216a promotes ovarian cancer proliferation and cisplatin resistance. Cisplatin 67-76 signal transducer and activator of transcription 3 Homo sapiens 0-5 30061175-8 2018 STAT3 is a regulator of miR-216a Strategies that inhibit miR-216a is a potential strategy for overcoming the cisplatin resistance in ovarian cancer. Cisplatin 109-118 signal transducer and activator of transcription 3 Homo sapiens 0-5 30145375-0 2018 Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis. Cisplatin 85-94 signal transducer and activator of transcription 3 Homo sapiens 39-44 30145375-5 2018 Furthermore, LC28 and its analogs suppress survival of cisplatin-resistant ovarian cancer cells by inhibiting STAT3 signaling and inducing apoptosis. Cisplatin 55-64 signal transducer and activator of transcription 3 Homo sapiens 110-115 30145375-6 2018 Therefore, these compounds may serve as candidate compounds for further modification and development as anticancer therapeutics targeting the DBD of human STAT3 for treatment of cisplatin-resistant ovarian cancer. Cisplatin 178-187 signal transducer and activator of transcription 3 Homo sapiens 155-160 30127934-0 2018 Oncostatin M treatment increases the responsiveness toward cisplatin-based chemoradiotherapy in cervical cancer cells in a STAT3-dependent manner. Cisplatin 59-68 signal transducer and activator of transcription 3 Homo sapiens 123-128 29767234-6 2018 Furthermore, the combination of miR-125a-5p and cisplatin markedly inactivated the STAT3 signaling pathway; however, interleukin (IL)-6, a widely reported activator of the STAT3 signaling pathway, reversed the suppressive effects of miR-125a-5p/cisplatin in ESCC cells on the activation of the STAT3 signaling pathway. Cisplatin 48-57 signal transducer and activator of transcription 3 Homo sapiens 83-88 29767234-6 2018 Furthermore, the combination of miR-125a-5p and cisplatin markedly inactivated the STAT3 signaling pathway; however, interleukin (IL)-6, a widely reported activator of the STAT3 signaling pathway, reversed the suppressive effects of miR-125a-5p/cisplatin in ESCC cells on the activation of the STAT3 signaling pathway. Cisplatin 245-254 signal transducer and activator of transcription 3 Homo sapiens 172-177 29767234-6 2018 Furthermore, the combination of miR-125a-5p and cisplatin markedly inactivated the STAT3 signaling pathway; however, interleukin (IL)-6, a widely reported activator of the STAT3 signaling pathway, reversed the suppressive effects of miR-125a-5p/cisplatin in ESCC cells on the activation of the STAT3 signaling pathway. Cisplatin 245-254 signal transducer and activator of transcription 3 Homo sapiens 172-177 29344640-0 2018 Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR. Cisplatin 64-73 signal transducer and activator of transcription 3 Homo sapiens 141-146 30024597-3 2018 Cisplatin (DDP) resistant cervical cancer cell line was established by shock induction to investigate the role of STAT3 in cervical cancer cells drug resistance. Cisplatin 0-9 signal transducer and activator of transcription 3 Homo sapiens 114-119 30024597-3 2018 Cisplatin (DDP) resistant cervical cancer cell line was established by shock induction to investigate the role of STAT3 in cervical cancer cells drug resistance. Cisplatin 11-14 signal transducer and activator of transcription 3 Homo sapiens 114-119 29844821-0 2018 Tumor-derived mesenchymal-stem-cell-secreted IL-6 enhances resistance to cisplatin via the STAT3 pathway in breast cancer. Cisplatin 73-82 signal transducer and activator of transcription 3 Homo sapiens 91-96 29844821-8 2018 Taken together, the findings of the present study indicated that BC-MSCs decreased the level of cisplatin-induced apoptosis in MCF-7 cells by activating the IL-6/STAT3 pathway in cancer cells. Cisplatin 96-105 signal transducer and activator of transcription 3 Homo sapiens 162-167 29280516-9 2018 Furthermore, combination therapy with S3-NTDi and cisplatin significantly decreased highly aggressive MYC-amplified MB cell growth and induced apoptosis by downregulating STAT3 regulated proliferation and anti-apoptotic gene expression. Cisplatin 50-59 signal transducer and activator of transcription 3 Homo sapiens 171-176 29286162-0 2018 GC7 enhances cisplatin sensitivity via STAT3 signaling pathway inhibition and eIF5A2 inactivation in mesenchymal phenotype oral cancer cells. Cisplatin 13-22 signal transducer and activator of transcription 3 Homo sapiens 39-44 30040917-7 2018 Moreover, knockdown of STAT3 expression significantly enhanced DIM antitumor activity and cisplatin sensitivity. Cisplatin 90-99 signal transducer and activator of transcription 3 Homo sapiens 23-28 29540490-7 2018 STAT3 inhibition with WP1066 decreased HOTAIR level and sensitized HNSCC to cisplatin or cetuximab. Cisplatin 76-85 signal transducer and activator of transcription 3 Homo sapiens 0-5 29505924-0 2018 LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation. Cisplatin 33-42 signal transducer and activator of transcription 3 Homo sapiens 103-108 29286162-6 2018 Further research revealed that the upregulation of p-STAT3 and c-Myc which was induced by the single treatment with either cisplatin or GC7 was significantly reversed by the GC7/cisplatin combination in mesenchymal phenotype Tca8113 and HN30 cells. Cisplatin 123-132 signal transducer and activator of transcription 3 Homo sapiens 53-58 29286162-6 2018 Further research revealed that the upregulation of p-STAT3 and c-Myc which was induced by the single treatment with either cisplatin or GC7 was significantly reversed by the GC7/cisplatin combination in mesenchymal phenotype Tca8113 and HN30 cells. Cisplatin 178-187 signal transducer and activator of transcription 3 Homo sapiens 53-58 29344640-6 2018 When EGFR protein expression was suppressed, PI3K, p-Akt, p-JAK2 and p-STAT3, decreased cyclin D1 and increased Bax protein expression in cisplatin-induced A549 cells by over-regulation of microRNA-133b. Cisplatin 138-147 signal transducer and activator of transcription 3 Homo sapiens 71-76 29344640-7 2018 Altogether, our results indicated that over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced NSCLC by PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR. Cisplatin 103-112 signal transducer and activator of transcription 3 Homo sapiens 148-153 29386467-10 2018 Cisplatin stimulated protein kinase B (Akt) and nuclear factor-kappaB (NF-kappaB) signaling pathways, but not mitogen-activated protein kinase (MAPK), activator protein 1 (AP-1) and signal transducer and activator of transcription 3 (STAT3) in SKOV3 cells. Cisplatin 0-9 signal transducer and activator of transcription 3 Homo sapiens 234-239 29091869-0 2018 Galangin (GG) combined with cisplatin (DDP) to suppress human lung cancer by inhibition of STAT3-regulated NF-kappaB and Bcl-2/Bax signaling pathways. Cisplatin 28-37 signal transducer and activator of transcription 3 Homo sapiens 91-96 29197940-0 2018 Thymoquinone Augments Cisplatin-Induced Apoptosis on Esophageal Carcinoma Through Mitigating the Activation of JAK2/STAT3 Pathway. Cisplatin 22-31 signal transducer and activator of transcription 3 Homo sapiens 116-121 29250186-0 2017 Knockdown of long non-coding RNA HOTAIR sensitizes hepatocellular carcinoma cell to cisplatin by suppressing the STAT3/ABCB1 signaling pathway. Cisplatin 84-93 signal transducer and activator of transcription 3 Homo sapiens 113-118 29036915-11 2017 This study has demonstrated that, in MDA-MB-231 cells, STAT3 rather than HIF-1alpha is important in mediating HICR to cisplatin. Cisplatin 118-127 signal transducer and activator of transcription 3 Homo sapiens 55-60 28428090-5 2017 The aim of this study was to develop and evaluate cationic solid lipid nanoparticles for delivery of RNAi-mediating plasmid DNA in order to down regulate STAT3 in cisplatin resistant lung cancer cells. Cisplatin 163-172 signal transducer and activator of transcription 3 Homo sapiens 154-159 28721072-0 2017 CXCL12 suppresses cisplatin-induced apoptosis through activation of JAK2/STAT3 signaling in human non-small-cell lung cancer cells. Cisplatin 18-27 signal transducer and activator of transcription 3 Homo sapiens 73-78 28878571-0 2017 Ribonucleic acid interference knockdown of IL-6 enhances the efficacy of cisplatin in laryngeal cancer stem cells by down-regulating the IL-6/STAT3/HIF1 pathway. Cisplatin 73-82 signal transducer and activator of transcription 3 Homo sapiens 142-147 28388577-0 2017 IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells. Cisplatin 49-58 signal transducer and activator of transcription 3 Homo sapiens 6-11 28388577-6 2017 Moreover, exogenous miR-204 blocked this circuit and enhanced cDDP sensitivity both in vitro and in vivo by inactivating IL-6R/STAT3 signaling and subsequently decreasing the expression of anti-apoptotic proteins. Cisplatin 62-66 signal transducer and activator of transcription 3 Homo sapiens 127-132 28903353-6 2017 Nuclear STAT3 expression was determined by immunohistochemistry and correlated with disease-free survival in retrospective cohorts of head and neck squamous cell carcinoma (HNSCC) patients treated with cisplatin-based chemoradiotherapy (n= 65) or with radiotherapy alone (n = 32). Cisplatin 202-211 signal transducer and activator of transcription 3 Homo sapiens 8-13 28903353-9 2017 Importantly, we found that active STAT3 in tumors directly correlated with response to cisplatin-based chemoradiotherapy in HNSCC patients (p = 0.006). Cisplatin 87-96 signal transducer and activator of transcription 3 Homo sapiens 34-39 28355175-0 2017 Synergistic Cytotoxicity of beta-Elemene and Cisplatin in Gingival Squamous Cell Carcinoma by Inhibition of STAT3 Signaling Pathway. Cisplatin 45-54 signal transducer and activator of transcription 3 Homo sapiens 108-113 28355175-8 2017 Cisplatin combined with beta-elemene decreased the expressions of p-STAT3, p-JAK2, and Bcl-2, and increased the expressions of Bax and caspase-3 significantly compared to cisplatin only treatment, as well as in the xenograft model. Cisplatin 0-9 signal transducer and activator of transcription 3 Homo sapiens 68-73 28355175-9 2017 CONCLUSIONS The results indicated that beta-elemene promoted the anti-proliferative and apoptotic effect of cisplatin by inhibiting STAT3 and blocking the JAK2-STAT3 signaling pathway in GSCC in vitro and in vivo. Cisplatin 108-117 signal transducer and activator of transcription 3 Homo sapiens 132-137 28355175-9 2017 CONCLUSIONS The results indicated that beta-elemene promoted the anti-proliferative and apoptotic effect of cisplatin by inhibiting STAT3 and blocking the JAK2-STAT3 signaling pathway in GSCC in vitro and in vivo. Cisplatin 108-117 signal transducer and activator of transcription 3 Homo sapiens 160-165 27524414-5 2017 Consistently, silencing of Stat3 in tumors reduced Jab1/Csn5 expression, thereby sensitizing NPC cells to cisplatin-induced apoptosis both in vitro and in vivo. Cisplatin 106-115 signal transducer and activator of transcription 3 Homo sapiens 27-32 27200496-0 2017 Epigallocatechin gallate sensitizes cisplatin-resistant oral cancer CAR cell apoptosis and autophagy through stimulating AKT/STAT3 pathway and suppressing multidrug resistance 1 signaling. Cisplatin 36-45 signal transducer and activator of transcription 3 Homo sapiens 125-130 28122338-7 2017 While, inhibition of miR-29b could prevent the cisplatin-induced epithelial features, cell movement and angiogenesis of CC cells, which means miR-29b/STAT3 axis participates in the chemotherapy of cisplatin in CC. Cisplatin 47-56 signal transducer and activator of transcription 3 Homo sapiens 150-155 28122338-7 2017 While, inhibition of miR-29b could prevent the cisplatin-induced epithelial features, cell movement and angiogenesis of CC cells, which means miR-29b/STAT3 axis participates in the chemotherapy of cisplatin in CC. Cisplatin 197-206 signal transducer and activator of transcription 3 Homo sapiens 150-155 28011380-8 2017 In genetic level, propofol could enhance the anti-tumor effect of cisplatin through EGFR/JAK2/STAT3 pathway. Cisplatin 66-75 signal transducer and activator of transcription 3 Homo sapiens 94-99 28011380-0 2017 Propofol enhances the cisplatin-induced apoptosis on cervical cancer cells via EGFR/JAK2/STAT3 pathway. Cisplatin 22-31 signal transducer and activator of transcription 3 Homo sapiens 89-94 28011380-9 2017 Further studies indicated that overexpression of EGFR and STAT3 is related to poor prognoses in cervical cancer patients, which contributed to confirm the clinical role of combined application of propofol and cisplatin. Cisplatin 209-218 signal transducer and activator of transcription 3 Homo sapiens 58-63 28011380-10 2017 CONCLUSION: Propofol enhances the cisplatin-induced cell apoptosis cervical cancer cells via EGFR/JAK2/STAT3 pathway and may be developed as a potential therapeutic agent to treat cervical cancer. Cisplatin 34-43 signal transducer and activator of transcription 3 Homo sapiens 103-108 27435393-9 2017 Furthermore, the EGFR/STAT3 pathway contributed to CDDP-induced CEBPD expression in UCUB cells. Cisplatin 51-55 signal transducer and activator of transcription 3 Homo sapiens 22-27 28255357-0 2017 STAT3/NF-kappaB-Regulated Lentiviral TK/GCV Suicide Gene Therapy for Cisplatin-Resistant Triple-Negative Breast Cancer. Cisplatin 69-78 signal transducer and activator of transcription 3 Homo sapiens 0-5 27435393-0 2017 Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder. Cisplatin 49-58 signal transducer and activator of transcription 3 Homo sapiens 23-28 27435393-4 2017 EXPERIMENTAL DESIGN: Loss-of-function assays were performed to elucidate the role of the EGFR and STAT3 in CDDP-induced CCAAT/enhancer-binding protein delta (CEBPD) expression in UCUB cells. Cisplatin 107-111 signal transducer and activator of transcription 3 Homo sapiens 98-103 28255357-14 2017 Moreover, STAT3/NF-kappaB signaling targeting could further sensitize tumor cells to cisplatin. Cisplatin 85-94 signal transducer and activator of transcription 3 Homo sapiens 10-15 26878391-7 2016 Moreover, we determined that miR-125a increased paclitaxel and cisplatin sensitivity by downregulating STAT3. Cisplatin 63-72 signal transducer and activator of transcription 3 Homo sapiens 103-108 27922075-0 2016 Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway. Cisplatin 43-52 signal transducer and activator of transcription 3 Homo sapiens 125-130 27845771-10 2016 Furthermore, we identified that miR-9600 augmented paclitaxel and cisplatin sensitivity by downregulating STAT3 and promoting chemotherapy-induced apoptosis. Cisplatin 66-75 signal transducer and activator of transcription 3 Homo sapiens 106-111 27564099-8 2016 Unlike 253J-Bv cells, T24 cells were co-treated with curcumin and cisplatin revealed an induction of apoptosis through decreased p-signal transducer and activator of transcription 3(STAT3) expression. Cisplatin 66-75 signal transducer and activator of transcription 3 Homo sapiens 182-187 27127878-5 2016 Mechanistically, we found that activation of FXR induced expression of small heterodimer partner (SHP), which in turn inhibited signal transducer and activator of transcription 3 (STAT3) phosphorylation and resulted in down-regulation of Bcl-xL expression in BTC cells, leading to increased susceptibility to CDDP. Cisplatin 309-313 signal transducer and activator of transcription 3 Homo sapiens 128-178 27127878-5 2016 Mechanistically, we found that activation of FXR induced expression of small heterodimer partner (SHP), which in turn inhibited signal transducer and activator of transcription 3 (STAT3) phosphorylation and resulted in down-regulation of Bcl-xL expression in BTC cells, leading to increased susceptibility to CDDP. Cisplatin 309-313 signal transducer and activator of transcription 3 Homo sapiens 180-185 26983899-8 2016 These results indicated that cisplatin- induced CCL5 secretion derived from the CAFs may promote cisplatin resistance, which was mediated by regulation of the STAT3 and PI3K/Akt signal pathways. Cisplatin 97-106 signal transducer and activator of transcription 3 Homo sapiens 159-164 27824145-6 2016 For the molecular mechanisms, CDDP alone increased the cancer stem cell (CSC)-like properties in gastric cancer cells via activating the interleukin-6 (IL-6)/IL-6 receptor (IL-6R)/signal transducer and activator of transcription 3 (STAT3) signaling. Cisplatin 30-34 signal transducer and activator of transcription 3 Homo sapiens 180-230 27824145-6 2016 For the molecular mechanisms, CDDP alone increased the cancer stem cell (CSC)-like properties in gastric cancer cells via activating the interleukin-6 (IL-6)/IL-6 receptor (IL-6R)/signal transducer and activator of transcription 3 (STAT3) signaling. Cisplatin 30-34 signal transducer and activator of transcription 3 Homo sapiens 232-237 27564099-9 2016 Moreover, pretreatment with U0126 suppressed curcumin and cisplatin-induced upregulation of p53, p21, and p-STAT3 and downregulation of survival proteins in both cells. Cisplatin 58-67 signal transducer and activator of transcription 3 Homo sapiens 108-113 27216197-8 2016 Unexpectedly, IL6-type cytokine signaling inducing STAT3 activation rendered cervical cancer cells significantly more susceptible to chemotherapeutic drugs, that is, cisplatin or etoposide. Cisplatin 166-175 signal transducer and activator of transcription 3 Homo sapiens 51-56 26983899-0 2016 Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K/Akt signaling pathways. Cisplatin 0-9 signal transducer and activator of transcription 3 Homo sapiens 113-118 26983899-8 2016 These results indicated that cisplatin- induced CCL5 secretion derived from the CAFs may promote cisplatin resistance, which was mediated by regulation of the STAT3 and PI3K/Akt signal pathways. Cisplatin 29-38 signal transducer and activator of transcription 3 Homo sapiens 159-164 26826383-0 2016 Cancer-associated fibroblasts attenuate Cisplatin-induced apoptosis in ovarian cancer cells by promoting STAT3 signaling. Cisplatin 40-49 signal transducer and activator of transcription 3 Homo sapiens 105-110 26826383-7 2016 In conclusion, our data suggested that CAFs could activate the anti-apoptotic STAT3 signaling, thereby decrease the Cisplatin-induced apoptosis and promote chemoresistance in ovarian cancer. Cisplatin 116-125 signal transducer and activator of transcription 3 Homo sapiens 78-83 26597704-3 2016 In this study, we found that the low-affinity leukotriene B4 receptor-2 (BLT2) and its ligand leukotriene B4 were highly up-regulated in cisplatin-resistant SK-OV-3 ovarian cancer cells and play critical roles in mediating the chemoresistance through the activation of signal transducer and activator of transcription-3 (STAT-3) and the subsequent up-regulation of interleukin-6 (IL-6). Cisplatin 137-146 signal transducer and activator of transcription 3 Homo sapiens 269-319 26597704-3 2016 In this study, we found that the low-affinity leukotriene B4 receptor-2 (BLT2) and its ligand leukotriene B4 were highly up-regulated in cisplatin-resistant SK-OV-3 ovarian cancer cells and play critical roles in mediating the chemoresistance through the activation of signal transducer and activator of transcription-3 (STAT-3) and the subsequent up-regulation of interleukin-6 (IL-6). Cisplatin 137-146 signal transducer and activator of transcription 3 Homo sapiens 321-327 26982182-10 2016 After CDDP treatment, greater volume reduction was observed in periostin-silenced xenograft tumors than in control tumors, which was accompanied by reduced levels of phosphorylated Stat3 and survivin in periostin-depleted tumors. Cisplatin 6-10 signal transducer and activator of transcription 3 Homo sapiens 181-186 25843419-0 2015 Dasatinib enhances cisplatin sensitivity in human esophageal squamous cell carcinoma (ESCC) cells via suppression of PI3K/AKT and Stat3 pathways. Cisplatin 19-28 signal transducer and activator of transcription 3 Homo sapiens 130-135 26373715-0 2016 Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells. Cisplatin 79-88 signal transducer and activator of transcription 3 Homo sapiens 17-22 26373715-2 2016 Knockdown expression of GP130 or STAT3 sensitized cells to anti-cancer drugs doxorubicin, cisplatin, and MEK inhibitor AZD6244. Cisplatin 90-99 signal transducer and activator of transcription 3 Homo sapiens 33-38 25586740-0 2015 MicroRNA-10a silencing reverses cisplatin resistance in the A549/cisplatin human lung cancer cell line via the transforming growth factor-beta/Smad2/STAT3/STAT5 pathway. Cisplatin 32-41 signal transducer and activator of transcription 3 Homo sapiens 149-154 25867391-0 2015 Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro. Cisplatin 156-165 signal transducer and activator of transcription 3 Homo sapiens 13-63 25867391-0 2015 Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro. Cisplatin 156-165 signal transducer and activator of transcription 3 Homo sapiens 65-70 25514838-0 2014 WP1066 sensitizes oral squamous cell carcinoma cells to cisplatin by targeting STAT3/miR-21 axis. Cisplatin 56-65 signal transducer and activator of transcription 3 Homo sapiens 79-84 23661500-8 2014 The findings were further supported using chemical inhibitors of STAT3 activity (a downstream effecter of uPAR signaling pathway), showing that STAT3 suppression altered HNSCC cell line cisplatin sensitivity. Cisplatin 186-195 signal transducer and activator of transcription 3 Homo sapiens 65-70 25213670-6 2014 In cisplatin-resistant cells with higher Jak2 and STAT3 expression, cisplatin and ruxolitinib combination dramatically suppressed the cell growth, down-regulated the expression of phosphorylated STAT3 and induced cleaved caspase-3 expression. Cisplatin 3-12 signal transducer and activator of transcription 3 Homo sapiens 50-55 25213670-6 2014 In cisplatin-resistant cells with higher Jak2 and STAT3 expression, cisplatin and ruxolitinib combination dramatically suppressed the cell growth, down-regulated the expression of phosphorylated STAT3 and induced cleaved caspase-3 expression. Cisplatin 68-77 signal transducer and activator of transcription 3 Homo sapiens 195-200 23661500-8 2014 The findings were further supported using chemical inhibitors of STAT3 activity (a downstream effecter of uPAR signaling pathway), showing that STAT3 suppression altered HNSCC cell line cisplatin sensitivity. Cisplatin 186-195 signal transducer and activator of transcription 3 Homo sapiens 144-149 23962558-3 2013 To provide evidence that supported the hypothesis that phosphorylated-Stat3 expression may promote cisplatin resistance, ectopic Stat3 was expressed by IL-6 stimulation that partially abrogates Stat3, as opposed to the knock-down of Stat3 by specific siRNA that restores cisplatin sensitivity against ovarian cancer cells. Cisplatin 271-280 signal transducer and activator of transcription 3 Homo sapiens 129-134 24944268-3 2014 Magnesium deficiency significantly increased cisplatin-associated weight loss and markers of renal damage (plasma blood urea nitrogen and creatinine), histological changes, inflammation, and renal cell apoptosis and modulated signaling pathways (e.g., ERK1/2, p53, and STAT3). Cisplatin 45-54 signal transducer and activator of transcription 3 Homo sapiens 269-274 24659656-0 2014 Suppression of STAT3 by chemically modified siRNAs increases the chemotherapeutic sensitivity of parental and cisplatin-resistant non-small cell lung cancer cells. Cisplatin 110-119 signal transducer and activator of transcription 3 Homo sapiens 15-20 24659656-8 2014 STAT3 suppression also significantly increased cisplatin sensitivity of Calu1 and CR-Calu1 cells after transfection with STAT3 siRNAs. Cisplatin 47-56 signal transducer and activator of transcription 3 Homo sapiens 0-5 24659656-9 2014 CONCLUSIONS: NSCLC cells could be sensitized to cisplatin by targeting STAT3 with chemically modified siRNAs together, a fact which was accompanied with increased apoptosis. Cisplatin 48-57 signal transducer and activator of transcription 3 Homo sapiens 71-76 23962558-0 2013 Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer. Cisplatin 54-63 signal transducer and activator of transcription 3 Homo sapiens 27-32 23962558-1 2013 The aim of the present study was to investigate the role of Stat3 in cisplatin resistant ovarian cancer. Cisplatin 69-78 signal transducer and activator of transcription 3 Homo sapiens 60-65 23962558-3 2013 To provide evidence that supported the hypothesis that phosphorylated-Stat3 expression may promote cisplatin resistance, ectopic Stat3 was expressed by IL-6 stimulation that partially abrogates Stat3, as opposed to the knock-down of Stat3 by specific siRNA that restores cisplatin sensitivity against ovarian cancer cells. Cisplatin 271-280 signal transducer and activator of transcription 3 Homo sapiens 129-134 23962558-2 2013 It was first demonstrated that higher activated Stat3 was detected in cisplatin-resistant ovarian cancer cell lines. Cisplatin 70-79 signal transducer and activator of transcription 3 Homo sapiens 48-53 23962558-3 2013 To provide evidence that supported the hypothesis that phosphorylated-Stat3 expression may promote cisplatin resistance, ectopic Stat3 was expressed by IL-6 stimulation that partially abrogates Stat3, as opposed to the knock-down of Stat3 by specific siRNA that restores cisplatin sensitivity against ovarian cancer cells. Cisplatin 271-280 signal transducer and activator of transcription 3 Homo sapiens 129-134 23962558-8 2013 Altogether, these findings emphasize the importance of Stat3 in cisplatin resistance in ovarian cancer and provide a further impetus to clinically evaluate biological modifiers that may circumvent cisplatin resistance in patients with chemoresistant ovarian cancer. Cisplatin 64-73 signal transducer and activator of transcription 3 Homo sapiens 55-60 23969971-0 2013 Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer. Cisplatin 75-84 signal transducer and activator of transcription 3 Homo sapiens 23-28 23526220-0 2013 Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway. Cisplatin 19-28 signal transducer and activator of transcription 3 Homo sapiens 57-107 23526220-4 2013 This study demonstrated a correlation between STAT3 phosphorylation and cisplatin cytotoxicity, using AS2 (PC14PE6/AS2)-derived cell lines (AS2/S3C) that contained constitutively active STAT3 plasmids as a model. Cisplatin 72-81 signal transducer and activator of transcription 3 Homo sapiens 46-51 23526220-5 2013 A STAT3 inhibitor (JSI-124) enhanced the cisplatin sensitivity in AS2 cells, whereas metformin inhibited STAT3 phosphorylation and enhanced cisplatin cytotoxicity. Cisplatin 41-50 signal transducer and activator of transcription 3 Homo sapiens 2-7 23969971-2 2013 Because oxaliplatin and nedaplatin are effective against cisplatin-resistant ovarian cancer in clinical trials and signal transducer and activator of transcription 3 (STAT3) is associated with cisplatin resistance, we investigated whether overcoming cisplatin resistance by oxaliplatin and nedaplatin was associated with the STAT3 pathway in ovarian cancer. Cisplatin 193-202 signal transducer and activator of transcription 3 Homo sapiens 115-165 23969971-2 2013 Because oxaliplatin and nedaplatin are effective against cisplatin-resistant ovarian cancer in clinical trials and signal transducer and activator of transcription 3 (STAT3) is associated with cisplatin resistance, we investigated whether overcoming cisplatin resistance by oxaliplatin and nedaplatin was associated with the STAT3 pathway in ovarian cancer. Cisplatin 193-202 signal transducer and activator of transcription 3 Homo sapiens 167-172 23969971-2 2013 Because oxaliplatin and nedaplatin are effective against cisplatin-resistant ovarian cancer in clinical trials and signal transducer and activator of transcription 3 (STAT3) is associated with cisplatin resistance, we investigated whether overcoming cisplatin resistance by oxaliplatin and nedaplatin was associated with the STAT3 pathway in ovarian cancer. Cisplatin 193-202 signal transducer and activator of transcription 3 Homo sapiens 115-165 23969971-2 2013 Because oxaliplatin and nedaplatin are effective against cisplatin-resistant ovarian cancer in clinical trials and signal transducer and activator of transcription 3 (STAT3) is associated with cisplatin resistance, we investigated whether overcoming cisplatin resistance by oxaliplatin and nedaplatin was associated with the STAT3 pathway in ovarian cancer. Cisplatin 193-202 signal transducer and activator of transcription 3 Homo sapiens 167-172 23546174-7 2013 Our results further demonstrate that AKT induces gastric cancer cells to become resistant to CDDP through the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathway. Cisplatin 93-97 signal transducer and activator of transcription 3 Homo sapiens 132-182 23969971-6 2013 The STAT3 pathway responded early to platinum drugs associated with cisplatin resistance in epithelial ovarian cancer and provided a rationale for new therapeutic strategies to reverse cisplatin resistance. Cisplatin 68-77 signal transducer and activator of transcription 3 Homo sapiens 4-9 23969971-6 2013 The STAT3 pathway responded early to platinum drugs associated with cisplatin resistance in epithelial ovarian cancer and provided a rationale for new therapeutic strategies to reverse cisplatin resistance. Cisplatin 185-194 signal transducer and activator of transcription 3 Homo sapiens 4-9 23665025-5 2013 Targeting STAT3 by siRNA technology markedly enhanced cisplatin-induced apoptosis in cisplatin-resistant ovarian cancer cells that expressed a high level of pSTAT3. Cisplatin 54-63 signal transducer and activator of transcription 3 Homo sapiens 10-15 23665025-5 2013 Targeting STAT3 by siRNA technology markedly enhanced cisplatin-induced apoptosis in cisplatin-resistant ovarian cancer cells that expressed a high level of pSTAT3. Cisplatin 85-94 signal transducer and activator of transcription 3 Homo sapiens 10-15 23665025-6 2013 Interleukin-6 (IL-6) could induce STAT3 activation in cisplatin-sensitive ovarian cancer cells and led to protection against cisplatin. Cisplatin 54-63 signal transducer and activator of transcription 3 Homo sapiens 34-39 23427943-8 2013 Cytotoxicity was not increased in cisplatin-treated SKOV3 by c-Src siRNA only or STAT3 siRNA only, but cell viability was decreased significantly in cisplatin-treated cells after simultaneous transfection with c-Src and STAT3 siRNAs. Cisplatin 149-158 signal transducer and activator of transcription 3 Homo sapiens 220-225 23546174-7 2013 Our results further demonstrate that AKT induces gastric cancer cells to become resistant to CDDP through the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathway. Cisplatin 93-97 signal transducer and activator of transcription 3 Homo sapiens 184-189 23546174-8 2013 Taken together, these data support a potential role for AKT overexpression and the JAK2/STAT3 pathway in the development of CDDP drug resistance in human gastric cancer cells. Cisplatin 124-128 signal transducer and activator of transcription 3 Homo sapiens 88-93 23426872-5 2013 The present study demonstrated the role of reactive oxygen species (ROS) in the induction of AKT regulation by cisplatin through the activation of JAK2/STAT3 at the transcriptional level in colon cancer cells. Cisplatin 111-120 signal transducer and activator of transcription 3 Homo sapiens 152-157 23436796-4 2013 Treatment with cisplatin or carboplatin increased the potency of tumor cell lines to induce IL-10-producing M2 macrophages, which displayed increased levels of activated STAT3 due to tumor-produced IL-6 as well as decreased levels of activated STAT1 and STAT6 related to the PGE(2) production of tumor cells. Cisplatin 15-24 signal transducer and activator of transcription 3 Homo sapiens 170-175 23426872-6 2013 HCT-116 cells treated with cisplatin exhibited increased JAK2 and STAT3 activities. Cisplatin 27-36 signal transducer and activator of transcription 3 Homo sapiens 66-71 23426872-10 2013 The JAK2/STAT3 pathway was also shown to mediate AKT expression and represents a potential target for overcoming cisplatin resistance in human tumors. Cisplatin 113-122 signal transducer and activator of transcription 3 Homo sapiens 9-14 22104727-7 2012 Inhibition of Stat3 function resulted in significant decreases in cisplatin resistance and enhanced apoptosis in drug resistant cells. Cisplatin 66-75 signal transducer and activator of transcription 3 Homo sapiens 14-19 23149124-5 2013 Stable silencing of STAT3 expression sensitized A549 cells to DNA damaging chemotherapeutics doxorubicin and cisplatin in a p53-independent manner. Cisplatin 109-118 signal transducer and activator of transcription 3 Homo sapiens 20-25 24083752-4 2013 After treatment with AZD1480 plus cisplatin, the apoptosis rate increased significantly while the expression level of p-STAT3 protein was decreased. Cisplatin 34-43 signal transducer and activator of transcription 3 Homo sapiens 120-125 23319321-8 2013 STAT3 silencing increased the susceptibility of ADAM8-overexpressing A549 cells to cisplatin. Cisplatin 83-92 signal transducer and activator of transcription 3 Homo sapiens 0-5 23319321-10 2013 Thus, ADAM8 is implicated in cisplatin resistance of NSCLC cells through activation of the STAT3 signalling pathway, and thus represents a potential therapeutic target in this malignancy. Cisplatin 29-38 signal transducer and activator of transcription 3 Homo sapiens 91-96 22961117-0 2012 Inhibition of the JAK-STAT3 signaling pathway by ganoderic acid A enhances chemosensitivity of HepG2 cells to cisplatin. Cisplatin 110-119 signal transducer and activator of transcription 3 Homo sapiens 22-27 22961117-7 2012 Furthermore, ganoderic acid A promoted cisplatin-induced cell death by enhancing the sensitivity of HepG2 cells to cisplatin mainly via the signal transducer and activator of transcription 3 suppression. Cisplatin 39-48 signal transducer and activator of transcription 3 Homo sapiens 140-190 22847808-10 2012 Let-7c directly repressed cisplatin-activated interleukin (IL)-6/STAT3 prosurvival pathway. Cisplatin 26-35 signal transducer and activator of transcription 3 Homo sapiens 65-70 22847808-12 2012 Let-7 modulates the chemosensitivity to cisplatin through the regulation of IL-6/STAT3 pathway in esophageal cancer. Cisplatin 40-49 signal transducer and activator of transcription 3 Homo sapiens 81-86 21909139-0 2012 Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells. Cisplatin 118-127 signal transducer and activator of transcription 3 Homo sapiens 35-40 21909139-5 2012 The inhibition of EGFR or Stat3 activity repressed Survivin, VEGF and Vimentin expression and the colony-forming potential, viability, motility and migration of the resistant cells, and sensitized them to cisplatin. Cisplatin 205-214 signal transducer and activator of transcription 3 Homo sapiens 26-31 21909139-8 2012 Hyperactive EGFR signaling through Stat3 and the Jak-Stat3 activity together promote ovarian cancer progression to cisplatin resistance and therefore represent targets for preventing the development of cisplatin resistance and the recurrent disease during cisplatin therapy in ovarian cancer. Cisplatin 115-124 signal transducer and activator of transcription 3 Homo sapiens 35-40 21909139-8 2012 Hyperactive EGFR signaling through Stat3 and the Jak-Stat3 activity together promote ovarian cancer progression to cisplatin resistance and therefore represent targets for preventing the development of cisplatin resistance and the recurrent disease during cisplatin therapy in ovarian cancer. Cisplatin 115-124 signal transducer and activator of transcription 3 Homo sapiens 53-58 21909139-8 2012 Hyperactive EGFR signaling through Stat3 and the Jak-Stat3 activity together promote ovarian cancer progression to cisplatin resistance and therefore represent targets for preventing the development of cisplatin resistance and the recurrent disease during cisplatin therapy in ovarian cancer. Cisplatin 202-211 signal transducer and activator of transcription 3 Homo sapiens 53-58 21909139-8 2012 Hyperactive EGFR signaling through Stat3 and the Jak-Stat3 activity together promote ovarian cancer progression to cisplatin resistance and therefore represent targets for preventing the development of cisplatin resistance and the recurrent disease during cisplatin therapy in ovarian cancer. Cisplatin 202-211 signal transducer and activator of transcription 3 Homo sapiens 53-58 22280969-13 2012 Importantly, diindolylmethane treatment potentiated the effects of cisplatin in SKOV-3 cells by targeting STAT3. Cisplatin 67-76 signal transducer and activator of transcription 3 Homo sapiens 106-111 21885917-0 2011 HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition. Cisplatin 39-48 signal transducer and activator of transcription 3 Homo sapiens 117-122 21875334-6 2012 We showed that aberrant expression and constitutive activation of STAT3 was instrumental in cisplatin resistance in ovarian cancer cell lines and in ovarian cancer tissue samples. Cisplatin 92-101 signal transducer and activator of transcription 3 Homo sapiens 66-71 22280969-1 2012 BACKGROUND: Signal transducer and activator of transcription 3 (STAT3) is activated in majority of ovarian tumors and confers resistance to cisplatin treatment in patients with ovarian cancer. Cisplatin 140-149 signal transducer and activator of transcription 3 Homo sapiens 12-62 22280969-1 2012 BACKGROUND: Signal transducer and activator of transcription 3 (STAT3) is activated in majority of ovarian tumors and confers resistance to cisplatin treatment in patients with ovarian cancer. Cisplatin 140-149 signal transducer and activator of transcription 3 Homo sapiens 64-69 19623660-9 2009 Inhibition of STAT3 by AG490 followed by treatment with cisplatin or taxol resulted in a significant increase in apoptosis suggesting that hypoxia-induced STAT3 activation is responsible for chemoresistance. Cisplatin 56-65 signal transducer and activator of transcription 3 Homo sapiens 155-160 20127005-0 2010 Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma. Cisplatin 50-59 signal transducer and activator of transcription 3 Homo sapiens 14-19 20127005-4 2010 We found that high expression levels of Stat3 and Notch1 were closely associated with cisplatin resistance respectively (P=0.014, P=0.000). Cisplatin 86-95 signal transducer and activator of transcription 3 Homo sapiens 40-45 20127005-5 2010 In addition, cisplatin resistance of HNSCC was decreased after inhibition of Stat3 or Notch signaling in vitro. Cisplatin 13-22 signal transducer and activator of transcription 3 Homo sapiens 77-82 20127005-6 2010 Our results provide first evidence that both high Stat3 and Notch1 expression are associated with cisplatin resistance in HNSCC patients, supporting the hypothesis that co-activation of Stat3 and Notch1 by their crosstalk induces the reprogrammed survival pathways in HNSCC responding to chemotherapy. Cisplatin 98-107 signal transducer and activator of transcription 3 Homo sapiens 50-55 20127005-6 2010 Our results provide first evidence that both high Stat3 and Notch1 expression are associated with cisplatin resistance in HNSCC patients, supporting the hypothesis that co-activation of Stat3 and Notch1 by their crosstalk induces the reprogrammed survival pathways in HNSCC responding to chemotherapy. Cisplatin 98-107 signal transducer and activator of transcription 3 Homo sapiens 186-191 19427998-4 2009 Significantly, STI571 increased the ability of cisplatin to inhibit constitutive activation of PI3K/Akt in BT-549 cells, synergized with camptothecin to increase the stability of IkappaB in MDA-MB-231 cells, and in MDA-MB-468 cells, camptothecin and 5-fluorouracil inhibited STI571-dependent activation of STAT3. Cisplatin 47-56 signal transducer and activator of transcription 3 Homo sapiens 306-311 15592503-6 2005 Blockade of STAT3 with the STAT3 decoy also induced apoptosis and decreased proliferation, an effect that was augmented when the STAT3 decoy was combined with cisplatin, both in vitro and in vivo. Cisplatin 159-168 signal transducer and activator of transcription 3 Homo sapiens 12-17 18059167-4 2007 When combined with cisplatin, YC-1 further promoted tumor cell apoptosis, decreased the expression of P-Stat3(705), Bcl-xL, CyclinD1 and survivin, and induced the cleavage of caspase 9 and PARP. Cisplatin 19-28 signal transducer and activator of transcription 3 Homo sapiens 104-109 18059167-6 2007 YC-1 inhibited Stat3 activity by enhancing the polyubiquitination of P-Stat3(705) induced by cisplatin. Cisplatin 93-102 signal transducer and activator of transcription 3 Homo sapiens 15-20 18059167-6 2007 YC-1 inhibited Stat3 activity by enhancing the polyubiquitination of P-Stat3(705) induced by cisplatin. Cisplatin 93-102 signal transducer and activator of transcription 3 Homo sapiens 71-76 18059167-8 2007 In conclusion, the present study demonstrated a novel anti-cancer effect of YC-1 in enhancing chemo-sensitivity of HCC cells to cisplatin through a Stat3 dependent manner. Cisplatin 128-137 signal transducer and activator of transcription 3 Homo sapiens 148-153 18196976-7 2008 Taken together, the results clearly suggested that NCX-4016 causes significant induction of cell cycle arrest and apoptosis in cisplatin-resistant human ovarian cancer cells via down-regulation of EGFR/PI3K/STAT3 signaling and modulation of Bcl-2 family proteins. Cisplatin 127-136 signal transducer and activator of transcription 3 Homo sapiens 207-212 15592503-6 2005 Blockade of STAT3 with the STAT3 decoy also induced apoptosis and decreased proliferation, an effect that was augmented when the STAT3 decoy was combined with cisplatin, both in vitro and in vivo. Cisplatin 159-168 signal transducer and activator of transcription 3 Homo sapiens 27-32 15592503-6 2005 Blockade of STAT3 with the STAT3 decoy also induced apoptosis and decreased proliferation, an effect that was augmented when the STAT3 decoy was combined with cisplatin, both in vitro and in vivo. Cisplatin 159-168 signal transducer and activator of transcription 3 Homo sapiens 27-32 34656559-7 2022 Inhibition of STAT3 or over expression of TTP can restore CDDP sensitivity of resistant NSCLC cells. Cisplatin 58-62 signal transducer and activator of transcription 3 Homo sapiens 14-19 15643501-0 2005 Overexpression of constitutive signal transducer and activator of transcription 3 mRNA in cisplatin-resistant human non-small cell lung cancer cells. Cisplatin 90-99 signal transducer and activator of transcription 3 Homo sapiens 31-81 15643501-5 2005 The mRNA expression of STAT3 was highest in cisplatin-resistant Ma-31 and lowest in cisplatin-sensitive Ma-46. Cisplatin 44-53 signal transducer and activator of transcription 3 Homo sapiens 23-28 15643501-5 2005 The mRNA expression of STAT3 was highest in cisplatin-resistant Ma-31 and lowest in cisplatin-sensitive Ma-46. Cisplatin 84-93 signal transducer and activator of transcription 3 Homo sapiens 23-28 15010843-6 2004 Meanwhile, cisplatin also inhibited Stat3 tyrosine phosphorylation and down-regulated BcL-XL anti-apoptotic protein in the cancer cells tested. Cisplatin 11-20 signal transducer and activator of transcription 3 Homo sapiens 36-41 10978511-0 2000 Structure and functional analysis of the human STAT3 gene promoter: alteration of chromatin structure as a possible mechanism for the upregulation in cisplatin-resistant cells. Cisplatin 150-159 signal transducer and activator of transcription 3 Homo sapiens 47-52 10978511-2 2000 We found that the STAT3 gene is overexpressed in cisplatin-resistant cells. Cisplatin 49-58 signal transducer and activator of transcription 3 Homo sapiens 18-23 10978511-7 2000 A transient expression assay using the luciferase reporter gene showed that the sequence from -403 to +102 possesses maximal promoter activity, and transcription of the STAT3 gene was significantly higher in cisplatin-resistant cells than in parental cisplatin-sensitive cells. Cisplatin 208-217 signal transducer and activator of transcription 3 Homo sapiens 169-174 10978511-7 2000 A transient expression assay using the luciferase reporter gene showed that the sequence from -403 to +102 possesses maximal promoter activity, and transcription of the STAT3 gene was significantly higher in cisplatin-resistant cells than in parental cisplatin-sensitive cells. Cisplatin 251-260 signal transducer and activator of transcription 3 Homo sapiens 169-174 34167436-0 2022 miR-4486 enhances cisplatin sensitivity of gastric cancer cells by restraining the JAK3/STAT3 signalling pathway. Cisplatin 18-27 signal transducer and activator of transcription 3 Homo sapiens 88-93 34167436-15 2022 miR-4486 overexpression could decrease viability and improve apoptosis of SGC-7901/DDP cells to revert its cisplatin-resistance, and the mechanism may be related to JAK3/STAT3 signalling pathway. Cisplatin 107-116 signal transducer and activator of transcription 3 Homo sapiens 170-175 34656559-8 2022 Collectively, our data showed that STAT3 and TTP-regulated expression of visfatin was involved in CDDP resistance of NSCLC cells. Cisplatin 98-102 signal transducer and activator of transcription 3 Homo sapiens 35-40 34549307-10 2021 A potential mechanism underlying SPHK1-induced cisplatin resistance and apoptosis inhibition may be activation of STAT3 via binding non-POU domain containing octamer binding. Cisplatin 47-56 signal transducer and activator of transcription 3 Homo sapiens 114-119 34612768-8 2021 Finally, CCT3 knockdown re-sensitized A549/DDP cells to cisplatin through inhibiting the Janus kinase 2/signal transducers and activators of transcription 3 (JAK2/STAT3) pathway. Cisplatin 56-65 signal transducer and activator of transcription 3 Homo sapiens 163-168 34329824-4 2021 Moreover, our findings showed that mechanistic target of rapamycin (mTOR), ribosomal protein S6 kinase (p70S6K), and signal transducer and activator of transcription (STAT3) inactivation was required for apoptosis induced by the combination of OZ-001 and cisplatin in in vitro and in vivo experiments. Cisplatin 255-264 signal transducer and activator of transcription 3 Homo sapiens 167-172 34139285-0 2021 Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma. Cisplatin 152-161 signal transducer and activator of transcription 3 Homo sapiens 125-130 34329824-0 2021 Improved tumor-suppressive effect of OZ-001 combined with cisplatin mediated by mTOR/p70S6K and STAT3 inactivation in A549 human lung cancer cells. Cisplatin 58-67 signal transducer and activator of transcription 3 Homo sapiens 96-101 34329824-5 2021 Our results suggest that combined treatment with OZ-001 and cisplatin could potentiate antiproliferative effects via suppression of the mTOR/p70S6K and STAT3 pathways and may be considered a potential therapeutic agent for NSCLC. Cisplatin 60-69 signal transducer and activator of transcription 3 Homo sapiens 152-157 34543857-0 2021 STAT3 contributes to cisplatin resistance, modulating EMT markers, and the mTOR signaling in lung adenocarcinoma. Cisplatin 21-30 signal transducer and activator of transcription 3 Homo sapiens 0-5 34543857-4 2021 It is known that STAT3 phosphorylation at Ser727 by mechanistic target of rapamycin (mTOR) is necessary for its maximal activation, but the crosstalk between STAT3 and mTOR signaling in cisplatin resistance remains elusive. Cisplatin 186-195 signal transducer and activator of transcription 3 Homo sapiens 17-22 34543857-4 2021 It is known that STAT3 phosphorylation at Ser727 by mechanistic target of rapamycin (mTOR) is necessary for its maximal activation, but the crosstalk between STAT3 and mTOR signaling in cisplatin resistance remains elusive. Cisplatin 186-195 signal transducer and activator of transcription 3 Homo sapiens 158-163 34543857-11 2021 Mechanistically, STAT3 partially coordinated the cisplatin resistance phenotype via the mTOR pathway in non-small cell lung cancer. Cisplatin 49-58 signal transducer and activator of transcription 3 Homo sapiens 17-22 34543857-12 2021 Thus, our findings reveal important targets and highlight the significance of the crosstalk between STAT3 and mTOR signaling in cisplatin resistance. Cisplatin 128-137 signal transducer and activator of transcription 3 Homo sapiens 100-105 34239773-10 2021 In treated patients, expression of COX-2 and arginase-1 in M-MDSCs was significantly decreased after two rounds of cisplatin, indicating inhibition of STAT3 signaling. Cisplatin 115-124 signal transducer and activator of transcription 3 Homo sapiens 151-156 34496932-11 2021 Cell sensitivity to cisplatin was rescued by ALKBH5 and HOXA10 knockdown or inhibition of the JAK2/STAT3 signaling pathway in EOC cells overexpressing ALKBH5-HOXA10. Cisplatin 20-29 signal transducer and activator of transcription 3 Homo sapiens 99-104 34496932-12 2021 CONCLUSIONS: The ALKBH5-HOXA10 loop jointly activates the JAK2/STAT3 signaling pathway by mediating JAK2 m6A demethylation, promoting EOC resistance to cisplatin. Cisplatin 152-161 signal transducer and activator of transcription 3 Homo sapiens 63-68 34216662-6 2021 Also, growing the cells in the scaffold sensitize the hepatocytes to the anti-tumor effect of cisplatin, by a mechanism involving the activation of ERK/p38alpha-MAPK and dysregulation of NF-kB/STAT3/Bcl-2 pathways. Cisplatin 94-103 signal transducer and activator of transcription 3 Homo sapiens 193-198 34375503-8 2021 Using the STAT3 inhibitor stattic to block the IL-6/STAT3 signaling pathway strongly increased the sensitivity of ZIPK-expressed cells to cisplatin. Cisplatin 138-147 signal transducer and activator of transcription 3 Homo sapiens 10-15 34375503-8 2021 Using the STAT3 inhibitor stattic to block the IL-6/STAT3 signaling pathway strongly increased the sensitivity of ZIPK-expressed cells to cisplatin. Cisplatin 138-147 signal transducer and activator of transcription 3 Homo sapiens 52-57 34375503-9 2021 In conclusion, ZIPK may play a role in cisplatin resistance through activation of the IL-6/ STAT3 signaling pathway. Cisplatin 39-48 signal transducer and activator of transcription 3 Homo sapiens 92-97 34375503-10 2021 Inhibition of STAT3 in gastric cancer overexpressing ZIPK might have potential to improve the efficacy of cisplatin. Cisplatin 106-115 signal transducer and activator of transcription 3 Homo sapiens 14-19 34321456-0 2021 miR-526b-3p inhibits lung cancer cisplatin-resistance and metastasis by inhibiting STAT3-promoted PD-L1. Cisplatin 33-42 signal transducer and activator of transcription 3 Homo sapiens 83-88 34094941-0 2021 lncRNA MIAT/HMGB1 Axis Is Involved in Cisplatin Resistance via Regulating IL6-Mediated Activation of the JAK2/STAT3 Pathway in Nasopharyngeal Carcinoma. Cisplatin 38-47 signal transducer and activator of transcription 3 Homo sapiens 110-115 34094941-8 2021 We find that the deficiency of the lncRNA MIAT/HMGB1 axis, inhibition of JAK2/STAT3, or neutralization of IL6 by antibodies significantly re-sensitizes resistant NPC cells to cisplatin in resistant NPC cells. Cisplatin 175-184 signal transducer and activator of transcription 3 Homo sapiens 78-83 35472743-6 2022 Fluorescent confocal and western blotting experiments proved that 6 significantly regulated NF-kappaB, EGFR, HIF-1alpha and phosphor-signal transducer and activator of transcription 3 (p-STAT3), and simultaneously inhibited PD-L1 expression to interrupt programmed cell death 1 (PD-1)/PD-L1 signaling pathway, suggesting a synergistic action of cisplatin and thalidomide. Cisplatin 345-354 signal transducer and activator of transcription 3 Homo sapiens 187-192 33982773-7 2021 Notably, the inhibition of PHF20 sensitized HSCC cells to cisplatin, thus increasing apoptosis via the signal transducer and activator of transcription 3 (STAT3)-myeloid cell leukemia-1 (MCL1) pathway. Cisplatin 58-67 signal transducer and activator of transcription 3 Homo sapiens 103-153 35599281-0 2022 Synergistic antitumor effect of Andrographolide and cisplatin through ROS-mediated ER stress and STAT3 inhibition in colon cancer. Cisplatin 52-61 signal transducer and activator of transcription 3 Homo sapiens 97-102 35599281-7 2022 Further studies showed that AP potentiates cisplatin-induced endoplasmic reticulum stress and STAT3 inhibition through increasing intracellular ROS. Cisplatin 43-52 signal transducer and activator of transcription 3 Homo sapiens 94-99 35599281-8 2022 Notably, pre-treatment of NAC, a ROS scavenger, reversed apoptosis induced by combined treatment of AP and cisplatin, while relieving the activation of endoplasmic reticulum stress as well as STAT3 inhibition. Cisplatin 107-116 signal transducer and activator of transcription 3 Homo sapiens 192-197 35628594-6 2022 In addition, nimodipine pre-treatment counteracted the reduction in LIM Domain Only 4 (LMO4) by cisplatin, which was associated with increased activation of Ak strain transforming/protein kinase B (Akt), cAMP response element-binding protein (CREB), and signal transducers and activators of transcription 3 (Stat3). Cisplatin 96-105 signal transducer and activator of transcription 3 Homo sapiens 254-306 35628594-6 2022 In addition, nimodipine pre-treatment counteracted the reduction in LIM Domain Only 4 (LMO4) by cisplatin, which was associated with increased activation of Ak strain transforming/protein kinase B (Akt), cAMP response element-binding protein (CREB), and signal transducers and activators of transcription 3 (Stat3). Cisplatin 96-105 signal transducer and activator of transcription 3 Homo sapiens 308-313 35139763-0 2022 Cancer-associated fibroblast exosomes promote chemoresistance to cisplatin in hepatocellular carcinoma through circZFR targeting signal transducers and activators of transcription (STAT3)/ nuclear factor -kappa B (NF-kappaB) pathway. Cisplatin 65-74 signal transducer and activator of transcription 3 Homo sapiens 181-186 33982773-7 2021 Notably, the inhibition of PHF20 sensitized HSCC cells to cisplatin, thus increasing apoptosis via the signal transducer and activator of transcription 3 (STAT3)-myeloid cell leukemia-1 (MCL1) pathway. Cisplatin 58-67 signal transducer and activator of transcription 3 Homo sapiens 155-160 33345849-9 2021 The In vivo studies confirmed the effect of IL-6 in increasing the chemoresistance of OvCa cells against cisplatin through the IL-6/STAT3/HIF-1alpha loop in the animal models. Cisplatin 105-114 signal transducer and activator of transcription 3 Homo sapiens 132-137 33878452-0 2021 Atezolizumab and blockade of LncRNA PVT1 attenuate cisplatin resistant ovarian cancer cells progression synergistically via JAK2/STAT3/PD-L1 pathway. Cisplatin 51-60 signal transducer and activator of transcription 3 Homo sapiens 129-134 33536189-8 2021 We found that cisplatin-loaded PLE-NPs induced apoptosis of STAT3-driven cells at lower doses compared to both unencapsulated cisplatin and cisplatin-loaded non-targeted NPs. Cisplatin 14-23 signal transducer and activator of transcription 3 Homo sapiens 60-65 32526010-7 2021 Besides, we isolated and cultured IL-23R+ human tumor cells from the post-operation tumor sample of three LC patients, and found that rhIL-23 could phosphorylate STAT3 (pSTAT3, residue Y705), which resulted in cancer cell proliferation and cisplatin resistance. Cisplatin 240-249 signal transducer and activator of transcription 3 Homo sapiens 162-167 33044324-0 2020 Long noncoding RNA nuclear-enriched abundant transcript 1 regulates proliferation and apoptosis of neuroblastoma cells treated by cisplatin by targeting miR-326 through Janus kinase/signal transducer and activator of transcription 3 pathway. Cisplatin 130-139 signal transducer and activator of transcription 3 Homo sapiens 182-232 33044324-9 2020 NEAT1 accelerated proliferation and weakened apoptosis of neuroblastoma cells treated by cisplatin by targeting miR-326 through activating JAK1/STAT3 signaling pathway, suggesting that NEAT1 was a potential biomarker against neuroblastoma. Cisplatin 89-98 signal transducer and activator of transcription 3 Homo sapiens 144-149 33634982-8 2021 Synergistic inhibition of the LIF/JAK1/STAT3 and NF-kB signaling pathways by ATO and 5-FU/cisplatin is a potential molecular mechanism underlying the differentiation effect. Cisplatin 90-99 signal transducer and activator of transcription 3 Homo sapiens 39-44 33634982-9 2021 CONCLUSIONS: ATO induced the differentiation of HCC CSCs and potentiated the cytotoxic effects of 5-FU/cisplatin through synergistic inhibition of the LIF/JAK1/STAT3 and NF-kB signaling pathways. Cisplatin 103-112 signal transducer and activator of transcription 3 Homo sapiens 160-165